# A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

> **NCT01906307** · PHASE1 · TERMINATED · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 6 (actual)

## Conditions studied

- Hepatorenal Syndrome Type I and Type II

## Interventions

- **DRUG:** LJPC-501

## Key facts

- **NCT ID:** NCT01906307
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Corporate decision
- **Last updated:** 2016-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01906307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01906307, "A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01906307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*